Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Decreases By 49.7%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 28,034 shares, a decrease of 49.7% from the January 29th total of 55,704 shares. Based on an average daily volume of 72,588 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.6% of the company’s shares are sold short. Currently, 0.6% of the company’s shares are sold short. Based on an average daily volume of 72,588 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 76.14% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

Galmed Pharmaceuticals Price Performance

NASDAQ GLMD traded down $0.04 during mid-day trading on Friday, hitting $0.61. The company’s stock had a trading volume of 16,760 shares, compared to its average volume of 72,599. The firm has a market capitalization of $3.35 million, a P/E ratio of -1.91 and a beta of 0.40. Galmed Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $3.50. The stock’s fifty day simple moving average is $0.74 and its two-hundred day simple moving average is $1.09.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.